Yan Tan – CEO, Xbiome, China
Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what makes its technology platform unique, and the challenges…
Address: Ocean Towers 15th Floor, 550 Yanan East Road, Shanghai ,China
Tel: +86 21 5306 0001
Web: http://www.zuelligpharma.com/
Zuellig Pharma was first established in Asia over 60 years ago and has become the leading healthcare distribution solution specialist in 15 countries and regions in Asia. Zuellig Pharma combines regional market expertise with constantly evolving quality services, IT systems, facilities and management in order to create enduring market partnerships based on trust, open communication, responsiveness, vision and top results.
In the past six decades, Zuellig Pharma has built up extensive experience in Asia Pacific, meeting the ever-changing needs of the market place through continuous innovation, efficiency and forward looking management. By combining extensive local market expertise with global vision and the latest technological developments Zuellig Pharma provides dedicated, cutting-edge distribution solutions to the healthcare industry. Zuellig Pharma’s state-of-the art facilities operate in strict accordance with rigorous quality management standards and set industry benchmarks for excellence.
Distribution services
Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what makes its technology platform unique, and the challenges…
2020 will certainly go down in history as a watershed year for the global community, as a new strain of coronavirus – later named SARS-CoV-19 – originating from the city…
A roundup of the latest news from Chinese biotechs, including a bumper IPO for Legend Biotech, a USD two million tie-up between Roche and Innovent Biologics, and a new Alphamab-Sanofi…
Johnson & Johnson’s network of healthcare innovation incubators, JLABS, opened its doors in Shanghai in June 2019 and now stands as the largest such institution of 13 globally. JLABS @…
Pierre A Morgon, SVP International Business for CanSino Biotechnology (CanSinoBIO) – a Chinese vaccine biotech developing one of the frontrunner COVID-19 vaccine candidates – shares how his extensive international career…
Highly potent neutralizing antibodies may be the key to laying a foundation for COVID-19 treatment, according to a Chinese research team led by Peking University. The worldwide race against…
A roundup of some of the top stories in China’s healthcare and life sciences industry, including challenges for Chinese biotechs in the post-pandemic era, why the country needs a biosecurity…
Dr Joan Shen, CEO of I-Mab Biopharma, shares her impressive career journey across companies like Pfizer, Janssen and Jiangsu Hengrui, before joining I-Mab, as well as introducing what I-Mab 2.0…
A roundup of the latest news in Chinese pharma, including a US IPO for Burning Rock Biotech, positive news on CanSino’s COVID-19 vaccine trials, and WuXi Biologics’s first US facility.…
Dr Sharon Chan, head of JLABS @ Shanghai – the first JLABS presence in Asia-Pacific as well as the largest globally – shares how Johnson & Johnson is investing in…
Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly adapting their portfolio strategies to launch products on the large but…
Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed commercial company with a successful USD 450 million IPO on…
See our Cookie Privacy Policy Here